TCM
MTNB icon

Towercrest Capital Management’s Matinas BioPharma MTNB Stock Holding History

Towercrest Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,734
Closed -$299K – 106
2024
Q2 		$299K Buy
+37,734
New +$342K 0.05% 90

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Towercrest Capital Management's MTNB Position: Q3 2024 in Review

Towercrest Capital Management sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 37,734 shares — an estimated $299K sold.

Towercrest Capital Management first reported a position in MTNB in Q2 2024 and held it in 1 quarter. The position peaked at $299K in Q2 2024. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Towercrest Capital Management reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Towercrest Capital Management sold 37,734 Matinas BioPharma shares in Q3 2024, an estimated $299K.
  • Towercrest Capital Management first reported a position in Matinas BioPharma in Q2 2024 and held it in 1 quarter.
  • Towercrest Capital Management's Matinas BioPharma position peaked at $299K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Towercrest Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.